Most Read Articles
22 hours ago
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Tristan Manalac, 5 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
2 days ago
Resistance training appears to confer significant benefits for inflammation and insulin pathway profiles in postmenopausal breast cancer survivors, according to a study. However, the magnitude and degree of benefit from exercise may be influenced by whether or not women gained strength and/or lost weight during exercise.
Pearl Toh, 2 days ago
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.

LABA/LAMA more effective than LAMA, LABA/ICS for COPD

Audrey Abella
22 May 2017

Fixed-dose combinations of long-acting β2-agonist (LABA) and muscarinic antagonist (LAMA) offered superior efficacy and comparable safety to LAMA or LABA/inhaled corticosteroid (ICS), the two most commonly prescribed first-line treatments for stable moderate-to-very-severe chronic obstructive pulmonary disease (COPD), according to a meta-analysis.

“The greater efficacy and comparable safety profiles observed with LABA/LAMA combinations vs LAMA or LABA/ICS support their potential role as first-line treatment options in COPD,” said the researchers.

Researchers pooled data from 18 studies (n=20,185) comprising trials comparing 12-week LABA/LAMA treatment with LAMA alone and/or LABA/ICS (using approved doses only) in patients with stable moderate-to-very severe COPD. [Int J Chron Obstruct Pulmon Dis 2017;12:907-922]

At week 12, LABA/LAMA-treated patients had significantly improved trough forced expiratory volume in 1 second vs LAMA alone and LABA/ICS (mean overall difference, 0.07, 95 percent confidence interval [CI], 0.05–0.09; p<0.0001 and mean overall difference, 0.08, 95 percent CI, 0.07–0.09; p<0.0001, respectively).

LABA/LAMA-treated patients also had significantly improved transitional dyspnoea index score (mean difference, 0.5, 95 percent CI, 0.32–0.68; p<0.0001) and St George’s Respiratory Questionnaire score (mean difference, -1.84, 95 percent CI, -2.31 to -1.37, p<0.0001) vs LAMA alone at week 12.

In terms of safety outcomes, lower adverse event (AE) rates were observed with LABA/LAMA vs LABA/ICS (risk ratio [RR], 0.94, 95 percent CI, 0.89–0.99; p=0.02), with significantly fewer incidences of pneumonia in the LABA/LAMA group (RR, 0.59, 95 percent CI, 0.43–0.81; p=0.001).

The researchers underlined the significance of pneumonia-related AEs due to the increased pneumonia risk associated with ICS alone or in combination with LABA, particularly with the ICS fluticasone. [Global Initiative for Chronic Obstructive Lung Disease, www.goldcopd.org, accessed May 18, 2017; Pulm Pharmacol Ther 2016;42:1-6; Lancet Respir Med 2013;1:210-223]

As salmeterol/fluticasone propionate was the only LABA/ICS comparator used in the analysis, and given the lack of direct comparison between LABA/LAMA and LABA alone, definitive conclusions on the relative efficacy of various treatments within the LABA/LAMA class cannot be made, hence the need for further evaluation of drug differences, said the researchers.

“LABAs improve symptoms and [health-related quality of life] more effectively than LAMAs, while LAMAs are superior to LABAs in reducing exacerbations,” said the researchers. Therefore, combining LABAs and LAMAs led to improved results that signified the advantage of dual bronchodilation over LAMA monotherapy or LABA/ICS combinations, they added.

“Including all available LABA/LAMA combinations … allowed us to provide indirect insights on the potential relative efficacy of these drugs … [W]e believe that our analysis provides clinically relevant, high-quality evidence that is applicable to daily clinical practice,” they said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 hours ago
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
Tristan Manalac, 5 days ago
Of the newly identified genetic loci for primary angle-closure glaucoma (PACG), two are significantly associated with primary angle-closure suspect (PACS), indicating involvement in the earlier stages of the disease, a recent Singapore study has shown.
2 days ago
Resistance training appears to confer significant benefits for inflammation and insulin pathway profiles in postmenopausal breast cancer survivors, according to a study. However, the magnitude and degree of benefit from exercise may be influenced by whether or not women gained strength and/or lost weight during exercise.
Pearl Toh, 2 days ago
Patients with inflammatory bowel disease (IBD) who had primary nonresponse to an anti-tumour necrosis factor (TNF) agent ─ or inadequate response to the initial loading doses ─ were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.